Progress in the development of immunotherapy for the treatment of patients with cancer

Abstract. Rosenberg SA (National Cancer Institute, Institutes of Health, Bethesda, MD, USA). Progress in the development of immunotherapy for the treatment of patients with cancer (Review). J Intern Med 2001; 250: 462–475.

[1]  S. Rosenberg,et al.  Isolation of a New Melanoma Antigen, MART-2, Containing a Mutated Epitope Recognized by Autologous Tumor-Infiltrating T Lymphocytes1 , 2001, The Journal of Immunology.

[2]  S. Rosenberg,et al.  Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. , 2001, Cancer research.

[3]  F. Marincola,et al.  Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. , 2000, Journal of the National Cancer Institute.

[4]  S. Rosenberg,et al.  Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.

[5]  H. Yamana,et al.  Induction of Human Leukocyte Antigen-A26–Restricted and Tumor-Specific Cytotoxic T Lymphocytes by a Single Peptide of the SART1 Antigen in Patients With Cancer With Different A26 Subtypes , 2000, Journal of immunotherapy.

[6]  J. Hipp,et al.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Steven A. Rosenberg,et al.  Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.

[8]  S. Rosenberg,et al.  T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. , 2000, Cancer journal.

[9]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[10]  S. Steinberg,et al.  Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response , 1999 .

[11]  F. Marincola,et al.  Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.

[12]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Rosenberg,et al.  Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. , 1999, Journal of immunotherapy.

[14]  G. Ogg,et al.  Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. , 1999, Journal of immunology.

[15]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[16]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[17]  S. Rosenberg,et al.  Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[18]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[19]  J. Shabanowitz,et al.  Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[20]  S. Rosenberg,et al.  Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4 (cid:49) T Cells , 1999 .

[21]  井上 佳子.  Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes , 1999 .

[22]  F. Marincola,et al.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. , 1998, Journal of the National Cancer Institute.

[23]  S. Rosenberg,et al.  A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. , 1998, Journal of immunology.

[24]  B. Seliger,et al.  Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? , 1998, Cancer research.

[25]  S. Rosenberg,et al.  Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. , 1998, The cancer journal from Scientific American.

[26]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[27]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[28]  J. Schlom,et al.  Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations. , 1997, Cellular immunology.

[29]  P. Coulie,et al.  Tumor antigens recognized by T cells. , 1997, Immunology today.

[30]  T. Eberlein,et al.  The HER2/neu‐derived peptide p654–662 is a tumor‐associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes , 1997, European journal of immunology.

[31]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[33]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[34]  S. Rosenberg,et al.  Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen , 1996, The Journal of experimental medicine.

[35]  河上 裕.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor , 1996 .

[36]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[37]  A. Levine,et al.  Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[39]  K. Sakaguchi,et al.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[40]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[41]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[42]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Rosenberg,et al.  Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] , 1995, The Journal of experimental medicine.

[44]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.

[46]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[47]  F. Chisari,et al.  The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. , 1994, Current topics in microbiology and immunology.

[48]  K. Kinzler,et al.  Association of the APC tumor suppressor protein with catenins. , 1993, Science.

[49]  E. Kieff,et al.  Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development , 1992, The Journal of experimental medicine.

[50]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[51]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[52]  S. Rosenberg,et al.  Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. , 1990, Journal of immunology.

[53]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[54]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[55]  C. Balch,et al.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor , 1988, The Journal of experimental medicine.

[56]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  S. Rosenberg,et al.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. , 1987, Journal of the National Cancer Institute.

[58]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[59]  S. Rosenberg,et al.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. , 1987, Journal of immunology.

[60]  A. Chang,et al.  High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. , 1986, JAMA.

[61]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[62]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[63]  S. Rosenberg,et al.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2 , 1985, The Journal of experimental medicine.

[64]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[65]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[66]  S. Rosenberg,et al.  In vitro growth of murine T cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens. , 1978, Journal of immunology.

[67]  S. Rosenberg,et al.  In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. , 1978, Journal of immunology.

[68]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.